Intercept Pharmaceuticals (ICPT) PT Set at $74.00 by Citigroup

Intercept Pharmaceuticals (NASDAQ:ICPT) has been assigned a $74.00 price target by Citigroup in a research report issued on Friday, December 29th. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 34.67% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Jefferies Group restated a “buy” rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, September 20th. Cowen restated a “buy” rating and set a $112.00 price objective (down previously from $232.00) on shares of Intercept Pharmaceuticals in a report on Friday, September 22nd. Seaport Global Securities restated a “buy” rating and set a $136.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, October 6th. Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a report on Wednesday, November 1st. Finally, Wedbush restated a “buy” rating and set a $253.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday, November 20th. Five investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $140.24.

Intercept Pharmaceuticals (ICPT) opened at $54.95 on Friday. The firm has a market capitalization of $1,380.00, a P/E ratio of -3.71 and a beta of -2.05. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12-month low of $52.11 and a 12-month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter in the previous year, the business earned ($3.59) EPS. Intercept Pharmaceuticals’s revenue was up 697.9% compared to the same quarter last year. analysts forecast that Intercept Pharmaceuticals will post -13.36 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. WFG Advisors LP lifted its stake in shares of Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares during the last quarter. Utah Retirement Systems lifted its stake in shares of Intercept Pharmaceuticals by 6.5% during the 2nd quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 200 shares during the last quarter. State of Wisconsin Investment Board lifted its stake in shares of Intercept Pharmaceuticals by 7.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock worth $432,000 after purchasing an additional 260 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Intercept Pharmaceuticals by 4.7% during the 2nd quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $847,000 after purchasing an additional 313 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Intercept Pharmaceuticals by 23.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 470 shares in the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/intercept-pharmaceuticals-icpt-given-a-74-00-price-target-at-citigroup.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply